CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+6.21%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$907M
AUM Growth
+$907M
(+28%)
Cap. Flow
+$180M
Cap. Flow
% of AUM
19.88%
Top 10 Holdings %
Top 10 Hldgs %
37.32%
Holding
435
New
22
Increased
336
Reduced
40
Closed
7
Top Buys
| 1 |
Apple
AAPL
|
$25.8M |
| 2 |
Microsoft
MSFT
|
$10.9M |
| 3 |
Amgen
AMGN
|
$7.28M |
| 4 |
NVIDIA
NVDA
|
$6.87M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$6.77M |
Top Sells
| 1 |
Micron Technology
MU
|
$6.44M |
| 2 |
ServiceNow
NOW
|
$5.1M |
| 3 |
Salesforce
CRM
|
$5M |
| 4 |
CrowdStrike
CRWD
|
$4.33M |
| 5 |
Qualcomm
QCOM
|
$3.38M |
Sector Composition
| 1 | Technology | 37.6% |
| 2 | Healthcare | 28.11% |
| 3 | Consumer Discretionary | 12.57% |
| 4 | Communication Services | 9.53% |
| 5 | Consumer Staples | 3.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Mirum Pharmaceuticals
MIRM
$3.75B
| $358K | 0.04% |
9,176
+3,639
| +66% | +$142K |
|
252
DexCom
DXCM
$30.9B
| $356K | 0.04% |
5,306
+2,692
| +103% | +$180K |
|
|
ANSS
253
DELISTED
Ansys
ANSS
| $353K | 0.04% |
1,108
+583
| +111% | +$186K |
|
254
Ligand Pharmaceuticals
LGND
$3.25B
| $352K | 0.04% |
3,514
+1,402
| +66% | +$140K |
|
255
Recursion Pharmaceuticals
RXRX
$2.02B
| $349K | 0.04% |
52,905
+25,851
| +96% | +$170K |
|
256
Fortrea Holdings
FTRE
$971M
| $345K | 0.04% |
17,233
+6,729
| +64% | +$135K |
|
257
Take-Two Interactive
TTWO
$44.1B
| $342K | 0.04% |
2,223
+1,193
| +116% | +$183K |
|
258
MannKind Corp
MNKD
$1.69B
| $333K | 0.04% |
52,890
+20,896
| +65% | +$131K |
|
259
Supernus Pharmaceuticals
SUPN
$2.52B
| $330K | 0.04% |
10,599
+4,140
| +64% | +$129K |
|
260
Zscaler
ZS
$42.1B
| $328K | 0.04% |
1,917
+1,016
| +113% | +$174K |
|
261
NovoCure
NVCR
$1.35B
| $325K | 0.04% |
20,814
+8,172
| +65% | +$128K |
|
262
Arvinas
ARVN
$580M
| $325K | 0.04% |
13,203
+5,163
| +64% | +$127K |
|
263
Rocket Pharmaceuticals
RCKT
$358M
| $323K | 0.04% |
17,505
+6,839
| +64% | +$126K |
|
264
Atlassian
TEAM
$44.8B
| $322K | 0.04% |
2,030
-8,428
| -81% | -$1.34M |
|
265
Syndax Pharmaceuticals
SNDX
$1.39B
| $315K | 0.03% |
16,367
+6,383
| +64% | +$123K |
|
266
Ardelyx
ARDX
$1.57B
| $312K | 0.03% |
45,280
+17,792
| +65% | +$123K |
|
267
Super Micro Computer
SMCI
$23.8B
| $309K | 0.03% |
+7,430
| New | +$309K |
|
268
Harrow
HROW
$1.38B
| $307K | 0.03% |
6,825
+2,668
| +64% | +$120K |
|
269
BioCryst Pharmaceuticals
BCRX
$1.74B
| $302K | 0.03% |
39,791
+15,544
| +64% | +$118K |
|
270
PVH
PVH
$4.1B
| $302K | 0.03% |
2,998
+2,055
| +218% | +$207K |
|
271
Kura Oncology
KURA
$732M
| $288K | 0.03% |
14,739
+5,788
| +65% | +$113K |
|
272
GlobalFoundries
GFS
$18.4B
| $282K | 0.03% |
6,996
+3,680
| +111% | +$148K |
|
273
Disc Medicine
IRON
$2.14B
| $281K | 0.03% |
5,717
+2,813
| +97% | +$138K |
|
274
Dynavax Technologies
DVAX
$1.19B
| $281K | 0.03% |
25,204
+9,827
| +64% | +$109K |
|
275
Nurix Therapeutics
NRIX
$723M
| $278K | 0.03% |
12,388
+5,419
| +78% | +$122K |
|